All About Medulloblastoma

Neha Vapiwala, MD and John P. Plastaras, MD, PhD
Updated by J. Taylor Whaley, MD
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: June 5, 2016

Some Background

Twenty percent of all childhood cancers start in the central nervous system (CNS), which consists of the brain, the spinal cord, and the surrounding fluid (cerebrospinal fluid, or CSF), lining tissues (meninges) and bone (cranium and vertebrae). Brain tumors are the most common solid tumor of childhood with 24.5 cases per 1 million children, per year and about 20% of those brain tumors found in children less than 3 years old. In the past several years, the incidence of pediatric CNS tumors has been increasing. This increase is partially explained by medical advances, including improved imaging, which has led to earlier detection and diagnosis of brain tumors.

There are many different types of pediatric CNS cancers. Two things determine the diagnosis, or type of tumor: 1) where in the CNS the tumor starts, or the location, and 2) how the tumor looks under a microscope, also known as the histology. Primary brain tumors are tumors that arise in the brain, while primary spinal tumors grow in the spinal cord. However, some brain tumors can spread to involve parts of the spine, and vice versa. On occasion, certain types of tumors can even spread to areas outside of the CNS, such as distant bones or bone marrow, which is called metastasis.

This is where the concept of "staging" the tumor comes into play, and each tumor type has its own specific staging system. The purpose of assigning a cancer stage is to help predict outcome as well as to guide treatment by appropriately applying what has been learned in pediatric cancer clinical trials. Ultimately, every cancer treatment plan is individualized for every patient, and takes into account not only the stage and clinical data, but also the goals and desires of the patient and his or her family.

What is medulloblastoma?

Medulloblastoma is a type of brain tumor that occurs in infants and young children. It represents about 20% of all pediatric CNS cancers. By definition, medulloblastomas occur in the cerebellum, which is the back part of the brain that controls walking, balance and fine motor coordination, among other things.

Medulloblastoma is a long name made up of three smaller words: medulla= Latin for marrow, meaning inner substance or core; blastos = Greek word for germ, meaning young, primitive, not fully developed; and oma = Greek for tumor. In other words, this is a tumor of primitive, undeveloped cells located inside the cerebellum.

Who gets this tumor, and how?

Medulloblastoma almost always occurs in children less than 15 years old. About 20% of the cases occur in infants less than two years old. There are approximately 400 cases diagnosed each year and the disease appears to be more common in boys than girls.

The exact cause(s) of medulloblastoma are not known. It does not appear to "run in families" or to be directly inherited from the parents. However, medulloblastoma is associated with certain chromosomal abnormalities that probably occur at some point during a child's development.

What are the signs of medulloblastoma?

The most common symptom of this tumor is frequent, severe vomiting, that may especially occur in the morning. Less commonly seen are morning headaches, nausea, confusion, and visual changes, such as double vision. Typically, children with medulloblastoma come to the attention of parents and teachers because of unsteady walking and clumsiness with holding things. All of these symptoms are consistent with a problem in the cerebellar region of the brain. For example, constant vomiting results from excessive pressure in the brain due to tumor blockage of important pathways for cerebrospinal fluid flow.

Please note that the symptoms mentioned here do not necessarily or automatically mean a child has a brain tumor, but further medical evaluation is required to rule out the possibility of a cerebellar tumor, such as medulloblastoma.

How is medulloblastoma diagnosed?

A magnetic resonance imaging (MRI) scan of the brain with gadolinium contrast-enhancement is the gold standard for detecting medulloblastoma. It has a very characteristic appearance on MRI scan: a well-defined, solid-looking mass located in the cerebellum, with fairly uniform contrast enhancement.

Medulloblastoma is a tumor type that can spread from the brain to the spine and/or cerebrospinal fluid (CSF). Thus, part of the diagnostic workup should also include a gadolinium-enhanced MRI of the spine. The search for disease spread to the spine can be supplemented with a lumbar puncture. This is a procedure in which a thin needle is inserted into the lower back in order to obtain a sample of the cerebrospinal fluid, looking for floating tumor cells (cytology). A definite diagnosis of medulloblastoma will generally be made only after the tumor cells are examined under a microscope by a pathologist.

How is medulloblastoma staged?

Staging is a way of grouping cancer patients with similar diagnoses and similar extent of disease. Most CNS tumors remain where they started, (ie: in the brain or in the spine), often referred to as "localized disease". However, medulloblastomas can spread within the central nervous system in a process called "metastasizing". Approximately 30% of medulloblastomas have spread (metastasized) to the CSF at diagnosis. Rarely, these tumor cells can gain access outside of the CNS and metastasize to distant bone or bone marrow.

The original Chang staging system was devised in the late 1960's, before the widespread use of radiology scans, relying primarily on information about tumor size and spread that is obtained during actual surgery, with the naked eye. A modified version of this system is now used for medulloblastoma, incorporating the presence or absense of metastases. Based on what the surgeon sees at the time of the surgery, the tumor is placed in one of the following categories (T referring to tumor):

  • T1: Tumor <3 cm in diameter
  • T2: Tumor >3 cm in diameter
  • T3a: Tumor >3 cm in diameter with spread to nearby structures
  • T3b: Tumor >3 cm in diameter with definite spread into the brain stem (part of brain that controls breathing, hearing, seeing, and other important functions)
  • T4: Tumor >3 cm in diameter with extension up past the aqueduct of Sylvius and/or down past the foramen magnum

In addition to "T" staging, medulloblastoma staging has been modified by including "M" staging, where the "M" stands for metastasis. Remember, this is a word that describes how far the tumor cells have spread from the original location, if at all. The M stage is determined not only by the surgeon's observations, but also in combination with MRI scans and lumbar cytology, and consists of 5 possible groups:

  • M0: No evidence of metastasis
  • M1: Tumor cells found in cerebrospinal fluid (by lumbar puncture and cytology study)
  • M2: Tumor beyond primary site but still in brain
  • M3: Tumor deposits ("seeds") in spine area that are easily seen on MRI
  • M4: Tumor spread to areas outside the CNS (outside both brain and spine)

Each patient is assigned a combination of one T stage and one M stage. As mentioned in the introduction, one of the reasons staging is important is that it helps predict how a patient might do in the long run, or how "curable" their cancer is, in a way. For medulloblastomas, the M stage is considered far more important in determining ultimate patient outcome and survival than the T stage.

Generally, treatment regimens are tailored to treat two groups: those with average risk and those with high-risk disease. Average risk patients are those that are older than 3 years, have no metastatic disease, and have less than 1.5 cc of residual tumor after surgery. If a child is under 3 years old, has metastatic disease, or has residual tumor left in the brain after surgery, he or she will be considered as having "high-risk" disease. Current trials are underway to further characterize medulloblastomas based on molecular aspects of tumor cells, but this approach remains investigational.

How is medulloblastoma treated?

Surgery

Surgery is typically the first component of therapy. It is very important to perform as complete a surgery as possible, with the goal being removal of all visible tumor, while sparing as much surrounding brain tissue as possible. This is then confirmed with a post-operative MRI scan of the brain to look for any leftover, or residual tumor. Based on what the MRI shows, the surgery is classified as one of the following:

  • Gross total resection = No evidence of any tumor left behind either at time of surgery or on post-surgery MRI
  • Near-total resection = More than 90% of original tumor removed by surgery
  • Subtotal resection = Anywhere from 51-90% of original tumor removed by surgery
  • Partial resection = Anywhere from 10-50% of original tumor removed by surgery
  • Any surgery that removed less than 10% of the original tumor is considered a biopsy, or sampling, of the tumor.

The ideal situation is a gross total resection, but this is not always possible. For example, sometimes the tumor is invading into or adhered to other parts of the brain, making safe surgery very difficult. Nonetheless, the overall goal is to take as much of the tumor out as possible without risking severe brain deficits, as the long-term survival of medulloblastoma patients is directly influenced by the degree of surgery. In other words, the more complete the surgery, the better the long-term outcome. This is also known as a maximal safe resection.

The surgeon attempts to balance the need to remove as much tumor as possible without damaging healthy brain tissue. Some children will develop a syndrome called as posterior fossa syndrome after brain surgery in the area of the cerebellum. This is associated with difficulty swallowing, balance deficits, mutism (a speech disorder that leaves the child unable to speak), poor muscle tone and emotional lability (changes in emotions). These neurologic deficits may remain for months, but usually improve slowly. Although historically this was seen in up to 15% of children, the rate of this has been noted to occur less commonly at pediatric neurosurgical centers.

Radiation Therapy

After surgery, external radiation to the entire CNS (craniospinal irradiation, or CSI) is recommended to prevent the tumor from coming back in this area (recurrence, or relapse). Even if complete surgery is performed, low-dose radiation to the brain and spine is very important for local control, local meaning within the CNS. This is the region that is most at-risk for the tumor returning.

After radiation of the whole brain and spine with a lower dose of radiation, the area of the original tumor, including where the surgeon operated, continues to receive radiation to a higher final dose (so-called radiation "tumor bed boost"). This is because the region in the brain where the tumor first started is the most likely place to still have some lingering, unseen, microscopic tumor cells. Historically, the entire cerebellum has been boosted to this higher radiation dose, putting normal structures including the inner ear and memory structures at risk for radiation damage. In recent studies, only the tumor bed has been boosted with similar success, which allows for protection of normal tissues. The development of intensity modulated radiation therapy (IMRT), a more precise form of radiation, also allows decreased radiation dose to important structures near the posterior fossa.

Much attention has understandably been paid to the possible long-term complications of radiation therapy to the brain and spine of a growing child. These can include deficits in memory, learning, social/emotional adjustment, hormone levels, hearing, and growth problems. The development of such side effects depend on many factors, including extent of pre-radiation surgery, amount and location of brain that is treated with radiation, age of the child at diagnosis, and how much radiation dose is given, among others. Because the side effects are very dependent on age (which is reflective of their stage of development), CSI is often deferred, or delayed by the use of chemotherapy, for children under the age of 3 years old.

However, modern radiotherapy techniques and proper attention to minimizing the radiation dose to important brain structures, whenever feasible, can allow for safe and effective treatment, even in younger children. While no therapy is without side effects, radiation therapy can be planned and delivered in such a way as to minimize potential long-term side-effects. This is best accomplished at a major radiation oncology center where physicians and staff are familiar with pediatric patients and technologically capable of treating childhood cancers.

Proton Radiotherapy

Even though the actual craniospinal volume that is irradiated is small, a large volume of normal tissue is exposed to radiation with photon radiotherapy (traditional radiation therapy), including the heart, lung, bowel, gonads, and vertebral bodies. Proton radiotherapy offers a major potential advantage over photons for the radiation of the spinal canal given its biologic properties. Photons (which are used in traditional radiation) enter the body, reach the tumor and continue through the body, exiting on the opposite side. This exposes the tissues in front and behind the tumor to radiation and, in turn, the risk for damage. Proton therapy works differently; entering the body and reaching it's peak dose at the tumor and stopping, exposing tissues in front of the tumor to lower doses of radiation and tissues behind the tumor to virtually no radiation. This translates into improved dose to the target volume while sparing normal tissues and reducing side effects and toxicity. Proton therapy can also prevent radiation dose to normal tissues for the cranial boost, especially for sensitive structures, such as the middle ear. Proton therapy is available at select centers worldwide and is used for many children who require radiotherapy for medulloblastoma.

Chemotherapy

At the present time, the role of chemotherapy in medulloblastoma is the standard of care as part of tri-modality therapy, along with surgery and radiation, to help increase long-term disease-free survival. Chemotherapy is standard adjuvant (after surgery) therapy for all patients, regardless of their risk stratification. Clinical trials for average risk medulloblastoma document disease-free survival at 5 years from diagnosis of about 85%. While this rate sounds good, it was achieved with chemotherapy agents such as cisplatin, vincristine, and CCNU, all of which have associated side effects, both short and long term. The use of chemotherapy has allowed for decreased radiation dose to the brain and spinal cord. This is very important in the attempt to decrease the toxicity of radiation. In younger patients, chemotherapy has an even more critical role; delaying radiation until the child is older and their developmental level is less susceptible to radiation damage. Clinical trials are underway that attempt to customize therapy by using molecular phenotyping to understand which patients need the most aggressive treatments, and which may be cured with less aggressive chemotherapy and lower radiation doses.

Follow-up Care and Survivorship

After treatment for childhood cancer, the patient will be followed closely to monitor for the cancer coming back, to help them heal from ongoing side effects, and to help them to transition to survivorship. Initially they will be seen often and have ongoing tests to monitor their health. As time goes on, these visits and testing will become less frequent. The oncology team will discuss each patient’s individual follow up plan with them.

Survivors often wonder what steps they can take to live healthier after cancer. There is no supplement or specific food you can eat to assure good health, but there are things you can do to live healthier, prevent other diseases, detect any subsequent cancers early and work with the social and emotional issues, including insurance, employment, relationships, sexual functioning, and fertility, that a prior cancer diagnosis sometimes brings with it. Your oncology team is there to support you and can help you find support resources.

It is important to have a plan for who will provide your cancer-focused follow up care (an oncologist, survivorship doctor or primary care doctor). Talk with your oncology team about developing a survivorship care plan. If you would like to find a survivorship doctor to review your history and provide recommendations, you can contact cancer centers in your area to see if they have a survivor's clinic or search for a clinic on OncoLink's survivorship clinic list.

References

Fangusaro J, Finlay J, Sposto R, Ji L, Saly M, Zacharoulis S, Asgharzadeh S, Abromowitch M, Olshefski R, Halpern S, Dubowy R,Comito M, Diez B, Kellie S, Hukin J, Rosenblum M, Dunkel I, Miller DC, Allen J, Gardner S. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. Pediatr Blood Cancer. 2008 Feb;50(2):312-8.

Halperin EC, Constine LS, Tarbell NJ, Kun LE. Pediatric Radiation Oncology. 4th Edition. Lippincott Williams & Wilkins (2005).

Merchant TE, Kun LE, Krasin MJ, Wallace D, Chintagumpala MM, Woo SY, Ashley DM, Sexton M, Kellie SJ, Ahern V, Gajjar A.Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys. 2008

Merchant TE, Hua CH, Shukla H, Ying X, Nill S, Oelfke U.. Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer. 2008 Jul;51(1):110-7.

Polkinghorn WR, Dunkel IJ, Souweidane MM, Khakoo Y, Lyden DC, Gilheeney SW, Becher OJ, Budnick AS, Wolden SL.. Disease Control and Ototoxicity Using Intensity-Modulated Radiation Therapy Tumor-Bed Boost for Medulloblastoma. Int J Radiat Oncol Biol Phys. 2011 Apr 9.

Medulloblastoma Overview from Medscape.

Keywords

Click on any of these terms for more related articles

Blogs

12 Simple Ways to Get Back Into Life With Cancer
by Marlys Johnson
July 19, 2016

The Day that Hell Came to Stay
by Paul Schilling
December 21, 2015

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
R
S
T
U
V
X
Y
Z
#
 
A
B
C
E
F
G
H
K
L
M
N
O
P
R
S
T
U
V
 
 
Stay informed with the latest information from OncoLink!   Subscribe to OncoLink eNews
View our newsletter archives